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Purpose: Protein kinase C (PKC) plays an important role in the regulation of retinal pigment epithelium (RPE) cell
proliferation. In this study, we investigated which of these isozymes could be responsible for the cell cycle and proliferation
in human RPE cells.
Methods: The effect of PKC activators on human RPE cell cycle progression was tested by flow cytometry. To identify
the isoform of PKC responsible for the increased progression of the cells through the cell cycle, we monitored the effect
of phorbol 12-myristate 13-acetate (PMA) on the subcellular localization of the nine PKC isoforms expressed in RPE
cells. To evaluate the molecular mechanism by which PKCα induces cell cycle progression, we examined the transcript,
protein, and cellular levels of cell cycle regulatory proteins using RT–PCR, western blotting, and a confocal microscope,
respectively.
Results: We demonstrated that PKC activation by PMA affected cell cycle progression in RPE cells. Of the nine PKC
isoforms that were present in RPE cells, we found PKCα was both necessary and sufficient to promote cell cycle progression
after being stimulated with PMA. Decreased PKCα expression resulted in a significant decrease in cell proliferation. The
only cell cycle-regulatory molecule whose expression was rapidly altered and decreased by PKCα activity was the cyclin-
dependent kinase (CDK) inhibitor p27kip1.
Conclusions: These results suggest that PKCα affects cell cycle progression and proliferation in human RPE cells through
the downregulation of p27kip1.
Protein  kinase  C  (PKC)  is  a  multigene  family  of
phospholipid-dependent  serine-threonine  kinases  that
mediates the phosphorylation of numerous protein substrates
in  signal  transduction.  It  plays  a  central  role  in  cellular
processes such as proliferation, differentiation, mitosis, and
inflammatory reactions [1,2]. Up to now, at least 12 isoforms
of PKC have been cloned to date, all displaying different
enzymatic  properties,  tissue  expression,  and  intracellular
localization [3,4]. PKCs are divided into three major groups
according to the variability of their regulatory domains. The
classic PKCs (cPKC: PKCα, PKCβI, PKCβII, and PKCγ) require
calcium, phosphatidylserine, and diacylglycerol (DAG), or
phorbol esters, for full activation. The novel PKCs (nPKC:
PKCδ, PKCε, PKCη, PKCθ, and probably PKCμ [5]) do not
require calcium or their activation. The third group are the
atypical  PKCs  (aPKC:  PKCζ,  PKCλ  and  PKCι),  whose
activation depends on phosphatidylserine, but not on DAG,
nor on calcium or phorbol esters. The differences in function
of specific PKC isoforms are mainly due to their subcellular
localization, their activation or inhibition by different stimuli,
and transcriptional regulation [6,7].
It  has  been  well  documented  that  the  PKC  family  is
involved  in  the  processes  of  proliferation,  migration,
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phagocytosis,  and  gel  contraction  in  retinal  pigment
epithelium (RPE) cells [8-14], which have all been implicated
in the pathogenesis of proliferative vitreoretinopathy (PVR).
For example, Harris et al. reported that hypericin, a specific
inhibitor of PKC, could have potential as a therapeutic drug
for PVR and that its antiproliferative and apoptotic effects on
RPE cells in vitro were in part mediated by PKC [9]. Another
study  showed  that  the  PKC  inhibitor  calphostin  C
dramatically affected the growth rate of RPE cells [10]. We
have found that hypericin has potential as a therapeutic drug
for PVR, potentially through its inhibition of the Ca2+ influx
pathway [15]. Rabbit models have shown that intravitreal
injection of hypericin is also a safe and effective means of
reducing  experimental  PVR  [16,17].  However,  since  the
distribution of PKC isoforms is both tissue-specific and cell
type-specific [18], the PKC activity is the sum of the isoforms
expressed in that tissue. Therefore, data regarding the precise
pattern  of  isoform  expression  in  RPE  cells  could  be
informative with regard to their physiologic regulation and
potential role in PVR [19]. Our previous study characterized
the expression pattern of all 12 PKC isoforms and showed that
ten  isoforms  (PKCα,  PKCβI,  PKCβII,  PKCδ,  PKCε,  PKCθ,
PKCμ, PKCζ, PKCλ, and PKCι) were present in cultured human
RPE  cells  [20].  This  identification  provides  the  first  step
toward elucidating their roles in RPE cell proliferation. In this
study, we further investigated which of these isozymes could
be responsible for the cell cycle in human RPE cells. Our
results  demonstrate  that  PKCα  controls  proliferation  and
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2683regulates  cell  cycle  progression  in  RPE  cells  through  the
downregulation of cyclin-dependent kinase (CDK) inhibitor
p27kip1.
METHODS
Reagents:  Trizol  reagent  was  obtained  from  Life
Technologies (Gaithersburg, MD). The SuperScript™ first
strand  synthesis  system  was  obtained  from  Invitrogen
(Carlsbad, CA). The enhanced chemiluminescence (ECL) kit
for western blotting was from Cell Signaling (Danvers, MA).
Rabbit polyclonal antibodies against p27 and phorbol 12-
myristate 13-acetate (PMA) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal PKCα, PKCγ,
PKCδ, PKCε, PKCη, PKCθ, PKCι, and PKCλ antibodies were
purchased from BD Systems (Torrance, CA). Monoclonal
PKCβI, PKCβII, PKCζ, and PKCμ antibodies were from Sigma
(St. Louis, MO). Anti-β actin was purchased from Boster
Biologic Technology, LTD (Wuhan, China). Thymeleatoxin
was  from  Biovision  (Mountain  View,  CA).  Small-
interference  (si)  RNA-PKCα  was  obtained  from  Ruibo
Biotech  (Guangzhou,  China).  Lipofectamine  2000  was
purchased from Invitrogen.
Human RPE cell culture: Human RPE cells were isolated
from five human donors, age 23 to 40 years, within 24 h after
death, which were obtained from the Zhongshan Ophthalmic
Center,  as  previously  described  [20].  This  project  was
approved  by  the  Ethics  Committee  of  the  Zhongshan
Ophthalmic Center, and followed the tenets of the Declaration
of  Helsinki.  Briefly,  the  anterior  segment,  vitreous  and
neurosensory retina were removed and an eye cup was made.
The RPE cells were immersed in a trypsin (0.05%)-EDTA
(0.02%) solution at 37 °C for 1 h. Culture medium with 20%
FBS was added, and the RPE were isolated and collected with
a pipette, using a dissecting microscope. Isolated cells were
centrifuged, resuspended and seeded to Corning culture plates
in Dulbecco’s modified Eagle medium (DMEM) containing
10% fetal bovine serum, penicillin G (100 μ/ml), streptomycin
sulfate  (100  mg/ml),  and  2mM  L-glutamate  in.
Experimentation was performed using 70%–80% confluent
cells at cell passage 3 to 8.
Flow cytometry: Confluent RPE cells were stimulated with
100 nM PMA, 100 nM thymeleatoxin and DMEM (as control
group) and collected at each time point, then incubated in PBS
(8.00 g/l sodium chloride, 0.20 g/l potassium chloride, 1.56 g/
l Na2HPO4.H2O, 0.20 g/l KH2PO4) containing 50 µg/ml/106
cells RNase A and 50 µg/ml/106 cells propidium iodide (PI)
for 30 min at 37 °C. The cell cycle analysis of treated cells at
each time point were done on FACScan Flow Cytometer
(Becton Dickinson). The red fluorescence (PI) from cells were
excited at 488 nm using channel 2. The distribution of cells in
different phases of the cell cycle was obtained by analyzing
fluorescence  intensities  with  Lysis  II  software  (Becton
Dickinson).
Reverse transcription-polymerase chain reaction: Total RNA
was  extracted  using  Trizol  reagent  according  to  the
manufacturer’s  procedure.  The  integrity  of  the  RNA  was
checked by 2% agarose gel electrophoresis. Approximately
5 µg RNA was reverse-transcribed following the protocol of
the  SuperScript™  first-strand  synthesis  system.  cDNAs
encoding the cell cycle regulator genes were amplified by
PCR as follows: denaturation for 30 s, annealing for 30 s and
elongation at 72 °C for 60 s. Primer sequences were designed
using Primer 3, as shown in Table 1. Each PCR was done a
minimum  of  three  times  with  each  set  of  primers.  PCR
products were analyzed by agarose (2%) gel electrophoresis
and ethidium bromide staining.
Preparation of cell extracts: The medium was removed and
washed twice with ice-cold PBS. The human RPE cells were
lysed with sample buffer that contained 60 mM Tris, pH 6.8,
2% (w/v) SDS, 100 mM 2-mercaptoethanol, and 0.01% (w/v)
bromophenol blue [21]. The lysates were then incubated on
ice  for  30  min.  The  extracts  were  harvested  using  a  cell
scraper, then boiled for 5 min and stored at –20 °C.
Western blot analysis: Cellular extracts from confluent human
RPE  cells  were  processed  for  western  blot  analysis  [22].
Briefly, 40 µg of protein per well was loaded on a 12% sodium
dodecyl  sulfate-  PAGE  (SDS–PAGE)  gel.  Protein  was
electrotransferred  to  polyvinylidene  difluoride  membranes
(Millipore) for 2 h at 350 mA, then blocked with a solution of
Tris-buffered saline (TBS) containing 5% nonfat milk and
0.1% Tween-20 (TBST) for 1 h, and incubated with primary
antibodies overnight at 4 °C. After three washes with TBST
for  10  min  at  room  temperature,  the  membranes  were
incubated with horseradish peroxidase-conjugated secondary
antibody for 3 h at room temperature, and then washed one
time with TBST for 30 min at room temperature. Localization
of antibodies was detected by chemiluminescence using an
ECL kit following the manufacturer’s instructions. Each PKC
isoform was examined in a minimum of four independent
experiments. As recommended by the supplier of the primary
antibodies, we used mouse brain lysate as a positive control.
Subcellular fractionation: Confluent cells were partitioned
into  soluble  and  particulate  fractions,  using  a  method
previously  described  [23,24].  Briefly,  cells  were  lysed  in
digitonin lysis buffer (as described in the previous section, but
without Triton X-100) and homogenized for 10 s at 3300× g
Digitonin-soluble  (cytosolic)  and  insoluble  (particulate)
fractions were separated by ultracentrifugation at 100,000× g
for 45 min at 4 °C. Supernatant was collected, and it formed
the cytosolic fraction. The pellet was resuspended in digitonin
buffer containing 1% Triton X-100, incubated on ice for 30
min, and cleared by centrifugation for 10 min at 10,000× g at
4 °C. Proteins were quantified by the Bio-Rad protein assay.
Samples were subjected to SDS–PAGE as described in the
previous section; 80 µg of protein were loaded per well.
Cell proliferation by thymeleatoxin or siRNA-PKCα: RPE
cells were cultured in 75 mm dishes (10×105 cells/dish) in
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were  incubated  with  100  nM  thymeleatoxin  for  24  h,  or
transfected with 100 nM siRNA using lipofectamine 2000
according  to  the  manufacturer's  protocol,  with  some
modifications. The cells were fed with transfection reagent in
serum-free  DMEM  for  24  h.  Three  independent  siRNAs
TABLE 1. PRIMERS AND PCR CONDITIONS OF CELL CYCLE REGULATOR GENES
Name Sequence Product size (bp) Tm (°C)
CDK1 F: TTTTCAGAGCTTTGGGCACT 195 55
R: CCATTTTGCCAGAAATTCGT
CDK2 F: CATTCCTCTTCCCCTCATCA 173 57
R: CAGGGACTCCAAAAGCTCTG
CDK3 F: TTTGCAGAGATGGTGACTCG 167 57
R: AGTCCCTTCCTGGTCCACTT
CDK4 F: GAAACTCTGAAGCCGACCAG 213 57
R: AGGCAGAGATTCGCTTGTGT
Cyclin A F: TTATTGCTGGAGCTGCCTTT 224 55
R: CTCTGGTGGGTTGAGGAGAG
Cyclin A1 F: ACCCCAAGAGTGGAGTTGTG 198 55
R: GGAAGGCATTTTCTGATCCA
Cyclin B1 F: CGGGAAGTCACTGGAAACAT 177 55
R: AAACATGGCAGTGACACCAA
Cyclin B2 F: TTGCAGTCCATAAACCCACA 218 55
R: GAAGCCAAGAGCAGAGCAGT
Cyclin C F: AGGCCCCACTCTTATGTCCT 231 59
R: TGGTGAAACCCCGTCTCTAC
Cyclin D1 F: AACTACCTGGACCGCTTCCT 204 57
R: CCACTTGAGCTTGTTCACCA
Cyclin D2 F: TGGGGAAGTTGAAGTGGAAC 175 57
R: ATCATCGACGGTGGGTACAT
Cyclin D3 F: TGGATGCTGGAGGTATGTGA 190 55
R: TGCACAGTTTTTCGATGGTC
Cyclin E1 F: CAGATTGCAGAGCTGTTGGA 225 57
R: TCCCCGTCTCCCTTATAACC
Cyclin E2 F: CAGGTTTGGAGTGGGACAGT 199 59
R: CTCCATTGCACACTGGTGAC
P16 F: CTCTGGAGGACGAAGTTTGC 158 57
R: CATTCCTCTTCCTTGGTTTCC
P18 F: TGCACAAAATGGATTTGGAA 223 51
R: GGGCAGGTTCCCTTCATTAT
P19 F: CTGCAGGTCATGATGTTTGG 229 57
R: CAGCAGTGTGACCCTCTTGA
P27 F: ATGTCAAACGTGCGAGTGTC 152 57
R: TCTCTGCAGTGCTTCTCCAA
P21 F: GACACCACTGGAGGGTGACT 172 59
R: CAGGTCCACATGGTCTTCCT
P107 F: CCAGTGGTGTGGTCAATCAG 164 59
R: GAACAGCGAGTTTGAGGAG
Rb F: GGAAGCAACCCTCCTAAACC 153 57
R: TTTCTGCTTTTGCATTCGTG
GAPDH F: ACCCAGAAGACTGTGGATGG 415 55
R: TGCTGTAGCCAAATTCGTTG
RNA (5 µg) was reverse-transcribed following the protocol of the SuperScript™ first-strand synthesis system. cDNAs encoding
the  cell  cycle regulator genes were amplified by PCR as follows: denaturation for 30 s, annealing for 30 s and elongation at
72 °C for 60 s. Primer sequences were designed using Primer 3.
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2685directed against PKCα (A1–A3) were used, along with one
control of scrambled siRNA (C): A1, dTd Ggc ugc uga cag
aca ucu uu; A2, dCd Acc uac cau guu caa cga au; A3, dTd Acc
gca gga caa cau acu uu; C, (product #2005527113152; Ruibo
Biotech,  Guangzhou,  China).  The  medium  containing
thymeleatoxin or siRNA-PKCαwas removed 24 h later.
Immunofluorescence analysis: Human RPE cells grown on
coverslips were stimulated for 24 h with 100 nM PMA, 100
nM thymeleatoxin, and 100 nM siRNA-PKCα. They were
fixed for 15 min in PBS containing 4% paraformaldehyde, and
then rinsed three times in PBS. All reagent incubations were
performed in a humidified chamber. The primary antibodies
were  incubated  for  16  h  in  a  solution  of  PBS  at  room
temperature; horse serum was used as the negative control
instead of the primary antibody. After washing four times for
10 min in PBS, FITC and Cy3 -labeled secondary antibodies
were incubated for 40 min at 37 °C. Then Hoechst 33342 was
incubated for 5 min at room temperature. After three rinses in
PBS, coverslips were mounted onto glass slides. Slides were
analyzed  on  a  Zeiss  laser  scanning  confocal  microscope
(LSCM510META). Each antibody was used in a minimum of
three separate experiments.
Data and statistical analysis: Results are expressed as mean
±standard deviation (SD). Statistical analyses were performed
upon  comparisons  using  one-way  ANOVA  (ANOVA).  A
value of p<0.05 was considered significant.
RESULTS
PKC  activation  with  a  phorbol  ester  affects  cell  cycle
progression:  Previous  work  has  shown  that  the  PKC
inhibitors, hypericin, and calphostin C, dramatically affect the
growth rate of RPE cells [9,10]; however, the identity of the
PKC isoform involved has remained unclear. To establish
which isoform of PKC is potentially involved, we tested the
effect  of  a  phorbol  ester,  PMA,  a  potent  activator  of
conventional  and  novel  PKC  isoforms,  on  the  cell  cycle
progression of human RPE cells. As shown in Figure 1A,B,
after 3 h following the addition of 100 nM PMA, RPE cells
entered the S phase. The numbers that entered into S phase at
6, 9, and 12 h time points in PMA-treated RPE cells were
decreased  when  compared  with  those  in  the  control  cells
(p<0.05). In contrast, the numbers that entered into the G2-M
phases of the cell cycle were increased between 3 and 12 h of
treatment, indicating that PMA can slightly affect progression
through the cell cycle. By 24 h of treatment, the distribution
of the cells between the different phases of the cell cycle was
similar to that of the control cells treated only with the vehicle
dimethyl  sulfoxide.  However,  control  cells  showed  no
significant change in distribution between the different phases
of the cell cycle during the 24 h time course examined.
To further confirm that cells were not blocked in the G2
phase, PI-stained RPE cells grown on glass coverslips were
analyzed  by  immunofluorescence  microscopy  at  various
times following PMA or vehicle treatment. Cells at all stages
of mitosis could be observed in both PMA-treated cells and
vehicle-treated cells, indicating that the cells were progressing
normally  through  mitosis  (Figure  1C).  Therefore,  PKC
activation seemed to play a role in the regulation of cell cycle
progression.
To  identify  the  isoform  of  PKC  responsible  for  the
progression of the cells through the cell cycle, we monitored
the effect of PMA on the subcellular localization of the nine
PKC isoforms expressed in human RPE cells. Translocation
of PKC from the cytosol to the membrane is a hallmark of its
activation [25]. Upon PMA treatment, only PKCα and PKCδ
were  translocated  from  the  cytosolic  to  the  particulate
fraction. PKCβII, PKCε, PKCθ, PKCζ, PKCι, PKCλ, and PKCμ
were not affected by PMA (Figure 2). PKCδ was completely
downregulated by proteolytic degradation by 6 h of treatment,
while  PKCα  was  translocated  from  the  cytosolic  to  the
particulate fraction between 3 h to 24 h of treatment. Hence,
the data indicate that of the nine PKC isoforms expressed in
RPE cells, only PKCα and PKCδ were significantly activated
by PMA stimulation.
PKCα  is  necessary  and  sufficient  to  affect  progression
through the cell cycle: To differentiate between PKCα and
PKCδ,  we  used  the  conventional  isoform-specific  PKC
agonist thymeleatoxin [26]. Since PKCα is the only one of the
three isoforms that translocates, it is likely that this agonist
would only affect PKCα.
Flow  cytometry  analysis  of  100  nM  thymeleatoxin-
treated RPE cells (Figure 3A) showed a cell cycle progression
profile  similar  to  that  obtained  with  PMA  (Figure  1A).
Western blot analysis confirmed that PKCα was specifically
translocated  (and  activated)  by  thymeleatoxin,  whereas
PKCδ remained unaffected (Figure 3B).
Further confirmation of the specific role of PKCα in the
regulation of the cell cycle progression of RPE cells was
provided by PKCα depletion experiments. RPE cells were
pretreated with PMA for 48 h to deplete the cells of their
endogenous PKCα. Cells were then restimulated with 100 nM
PMA  and  100  nM  thymeleatoxin,  and  their  distribution
between the different phases of the cell cycle was analyzed
between 0 and 30 h following restimulation by flow cytometry
(Figure 3C). In the absence of a detectable level of PKCα, there
was no significant change in the cell cycle progression of RPE
cells following PMA or thymeleatoxin stimulation over the
30-h  time  course  (Figure  3C),  unlike  the  case  of  cells
containing PKCα (Figure 1).
Although  PKC  or  PKCα  activation  affects  cell  cycle
progression, the proliferation of the PKC isoform involved has
remained unclear. The role of PKCα in cell proliferation was
further  addressed  using  siRNA  or  thymeleatoxin.  Equally
seeded  cultures  were  grown  and  counted,  giving  a  direct
reading of their growth rate. SiRNA-PKCα clones exhibited a
growth rate of about half the rate of the control cells (Figure
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2686Figure  1.  PKC  activation  with  PMA
affects cell cycle in human RPE cells.
Flow  cytometry  analysis  of  PMA-
treated RPE cells (A) shows decreased
S phase and increased G2-M phases cell
numbers when compared with that of
untreated RPE cells (B). For each side
scatter plot, the y-axis is the number of
cells,  while  the  x-axis  is  the  DNA
content. Values from each scatter plot
are  graphed  below  panels  A  and  B.
Similar  results  after  PMA  treatment
were  obtained  in  eight  independent
experiments.  C:  Immunofluorescence
of cellular DNA stained with propidium
iodide (PI) showed cells in interphase or
at different stages of mitosis. RPE cells
were grown on glass coverslips for 24 h,
treated  either  with  PMA  or  with
thymeleatoxin for 9 h, and then fixed.
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26873D), thus indicating that PKCα levels are directly proportional
to the basal proliferation rate of RPE cells. However, PKCα
agonist, thymeleatoxin, did not exhibit a growth rate of the
RPE cells (Figure 3D), indicating that thymeleatoxin has no
significant effect on cell proliferation. Altogether, the data
strongly suggest that PKCα-specific activation is necessary
and sufficient for the regulation of human RPE cells through
the cell cycle. Moreover, our data indicate that PKCα affects
RPE  cell  proliferation,  since  decreased  PKCα  expression
correlates with decreased proliferation.
p27kip1 mRNA and protein levels are downregulated following
PKCα  activation:  As  shown  in  Figure  4A,  PKCα  can  be
downregulated at the 3-h time point following 24 h of siRNA-
PKCα  treatment,  but  not  upregulated  following  PMA  and
thymeleatoxi  treatment.  To  evaluate  the  molecular
mechanism by which PKCα induces cell cycle progression, we
used RT–PCR to examine the transcript levels of cell cycle-
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Figure 2. PKCα and PKCδ, are the only
isoforms translocated by PMA in RPE
cells. A:  Shown  is  a  western  blot
analysis of the subcellular distribution
between  cytosolic  and  membrane
fractions  of  the  nine  PKC  isoforms
expressed  in  RPE  cells.  RPE  protein
extracts were fractionated into cytosolic
(C) and particulate (P) fractions; 80 µg
of protein was loaded in each well. Only
PKCα  and  PKCδ  were  translocated in
response to PMA. PKCδ was completely
downregulated  by  proteolytic
degradation by 6 h of treatment, while
PKCα  was  translocated  from  the
cytosolic to the particulate fraction from
3 h to 24 h. Note that in the doublet
obtained for PKCδ, only the upper band
(78  kDa)  is  the  active  form  of  the
enzyme. B:  Optical  density  of  PKCα
determined by densitometric imaging is
shown (Mean±SD; n=4). The contents
at different time points are statistically
different (F=2.337, p<0.05). The β-actin
band  with  42  kDa  is  used  for
quantitation.Figure 3. PKCα is necessary and sufficient to affect cell cycle progression. A: Flow cytometry analysis of RPE cells after 100 nM thymeleatoxin
treatment shows a cell cycle progression profile similar to that obtained with PMA in eight experiments. B: western blot analysis shows that
PKCα was rapidly translocated to the membrane by thymeleatoxin and downregulated within 24 h, the protein remained undetectable after 48
h of treatment, however, PKCδ was not translocated and was not downregulated at all time points. Eighty micrograms of protein was loaded
in each well. Optical density of PKCα determined by densitometric imaging is shown (Mean±SD, n=3). The β-actin band with 42 kDa is used
for quantitation. C: Flow cytometry analysis of RPE cells shows that there was no significant change in the cell cycle progression following
PMA or thymeleatoxin restimulation when compared with the control over the 30 h time course after 48 h of PMA treatment. D: PKCα activity
regulates the growth rate of RPE cells. Approximately 110,000 RPE cells were seeded and then incubated with thymeleatoxin or siRNA-
PKCα for 24h. The numbers of cells were counted using a Coulter Counter and displayed in the top panel (* p<0.0001). Western blot using
an anti-PKCα antibody showed that the total PKCα level was dramatically decreased in siRNA-PKCα treated cells; 40 µg of protein was loaded
in each well.
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2689regulatory proteins after 3 h of treatment. We found that p27
mRNA  was  obviously  downregulated  following  PMA  or
thymeleatoxin treatment, and upregulated following siRNA-
PKCα  treatment.  Levels  of  other  mRNA  (CDK1,  CDK2,
CDK3, CDK4, Cyclin B1, Cyclin B2, Cyclin D2, Cyclin D3,
Cyclin  E1,  Cyclin  E2,  p16,  p18,  p21,  and  Rb)  remained
unaffected by PKCα activation. The mRNAs for CyclinA1,
CyclinC, CyclinD1, p19, and p107, could not be detected in
this assay (Figure 4B). During 24 h of stimulation with PMA
or  thymeleatoxin,  p27  mRNA  was  strongly  and  rapidly
downregulated at 1, 2, and 6 h following PMA treatment, or
at 1 h and 2 h following thymeleatoxin treatment (Figure
4C,D).
Consistent with a change at the mRNA level, the p27
protein was also downregulated over a 24-h period following
PMA or thymeleatoxin treatment of RPE cells (Figure 5). In
untreated RPE cells, the p27 protein level remained constant,
while in cells treated either with PMA or thymeleatoxin, p27
was strongly downregulated at the 1 h and 3 h time points.
These data indicate that p27kip1 is the only cell cycle-regulatory
molecule downregulated following PKCα activation.
Figure  4.  Downregulation  of  the
p27Kip1 gene following PKCα activation.
A: PKCα mRNA level is downregulated
at the 3 h point following 24 h of siRNA-
PKCα  (lane  2)  treatment,  but  not
upregulated  following  PMA  (lane  4)
and  thymeleatoxi  (lane  3)  treatment.
lane 1, control. B: p27kip1 mRNA level
is downregulated following 3 h of PMA
(lane  4)  and  thymeleatoxi  (lane  3)
treatment  and  upregulated  following
siRNA-PKCα (lane 2) treatment. lane 1,
control. Five micrograms of RNA was
used  for  each  reaction.  C:  RT–PCR
analysis of RPE cells stimulated with 24
h  PMA  and  thymeleatoxin  treatment
shows a strong downregulation of the
p27 mRNA at 1, 2, and 6 h following
PMA,  or  at  1  and  2  h  following
thymeleatoxin  treatment.  D:  Optical
density of P27 mRNA determined by
densitometric imaging is shown (Mean
±SD, n=4). The GAPDH band is used
for quantitation.
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2690Immunofluorescence  colocalization  of  PKCα  and  P27:
Confocal microscopy clearly showed that the cultured RPE
cells  formed  monolayers  with  typical  polygonal  cellular
arrays. As shown in Figure 6, PKCα and p27 have obvious
cytoplasmic localizations and slight nuclear localization, and
mostly colocalized in the cytoplasm of the cells. Although
minor staining differences appeared among 100 nM PMA,
100  nM  thymeleatoxin,  and  100  nM  siRNA-PKCα  when
compared with that of control group, PKCα and p27 seemed
colocalized in the cytoplasm of the cells with decreased cell
numbers in siRNA-PKCα.
DISCUSSION
Effect of PKCα on the cell cycle progression in RPE cells: We
have found that PKC activation by phorbol esters affected
RPE  cell  progression  through  the  cell  cycle.  This  was
consistent with previous data showing the correlation between
the results on PKC activity and RPE cell proliferation [10] and
the  animal  results  that  demonstrated  inhibitors  of  PKC
hypericin could have efficacy in rabbits with PVR [16,17].
Moreover, we have determined that only PKCα activation is
necessary and sufficient to regulate cell cycle progression of
RPE cells, and that the expression level of PKCα correlates
with the proliferation of RPE cells.
It is well known that PKC has been associated with the
regulation of cell cycle progression either during the G1-to-S
progression or during the G2/M transition [27-29]. PKC has
been shown to regulate G1 progression through the modulation
of  CDK  activity,  either  by  modifying  cyclin  or  CDK
expression  levels,  or  by  modifying  the  expression  of  the
cyclin-CDK inhibitors. Due to the relevance of PKC isozymes
in the control of cell cycles, both in G1/S and in G2/M, the
elucidation  of  such  complex  intracellular  networks  using
cellular  and  animal  models  has  become  of  the  outmost
importance.
Predominantly, PKC plays an inhibitory role in many cell
cycle progressions [23,30,31]. In intestinal epithelial cells, for
instance, PKCα-specific activation resulted in G1 arrest and
delayed transit through the S and G2/M phases through an
upregulation  of  p21  and  p27,  resulting  in
hypophosphorylation of Rb [23]. However, in contrast to most
cell types, phorbol esters accelerated growth factor-induced
Swiss 3T3 cell cycle entry and progression into the S phase
by  elevating  cyclin  D1  levels  and  downregulating  p27Kip1
expression [32]. In human RPE cells, ethambutol may exert
toxic effects in RPE, including the suppression of cell growth,
formation  of  cytoplasmic  vacuoles,  and  reduction  of
phagocytic  functions  via  the  PKC  signal  pathway  [33].
Alkylphosphocholines inhibit proliferation of RPE cells and
RPE-mediated  matrix  contraction  in  vitro  at  nontoxic
concentrations through the inhibition of PKC activity [34].
Figure  5.  Downregulation  of  the
p27Kip1  protein  following  PKCα
activation. A: Western blot analysis of
RPE  cells  treated  24  h  with  100  nM
PMA  and  100  nM  thymeleatoxin
reveals a strong downregulation of the
p27 protein at the 1 h and 3 h time points.
Gels show representative results of four
independent  experiments.  Each  well
was loaded with 40 µg of protein. B:
Optical  density  of  P27  protein
determined by densitometric imaging is
shown  (Mean±SD,  n=4).  The  β-actin
band  with  42  kDa  is  used  for
quantitation.
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2691Figure 6. Confocal images of p27 and PKCα colocaliztion in RPE cells. PKCα and p27 have obvious cytoplasmic localizations and slight
nuclear localization, and mostly colocalized in the cytoplasm of the cells stimulated with PMA, thymeleatoxin, and siRNA- PKCα. PKCα
(FITC, green label) p27 (Cy3, red label), nuclei (Hotchest 33342, blue label), PKCα, and p27 colocalization (yellow label).
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2692Our study is the first to show that the activation of PKC,
and  specifically  PKCα,  exerts  effects  on  the  S  to  G2/M
progression of the human RPE cell cycle, as shown in Figure
1A and Figure 3A, and that the inhibition of PKC decreases
the  proliferation,  as  shown  in  Figure  3D.  Recently,
aprinocarsen,  an  antisense  oligonucleotide  (ASO)  against
PKCα, has been used to decrease the malignant proliferation
in clinic trials in different cancers [35-39]. Similarly, since
PKCα was the only isoform associated with the proliferation
of RPE cells in our study, it may be a rational approach for
targeted therapies against RPE cell proliferation and PVR
disease.
Downpregulation of p27kip1 following PKCα activation in RPE
cells: To elucidate the mechanism by which PKC increased
the RPE cell cycle progression, we analyzed the expression of
various  cell  cycle-regulatory  proteins  following  PKC
activation. We found that the only cell cycle regulatory protein
downregulated by PKCα activity was the inhibitor p27kip1,
which has been proposed to be part of a cell-intrinsic timer
that arrests the cell cycle and initiates differentiation in several
lineages [40,41].
Several  groups  have  reported  gigantism  and  multiple
organ hyperplasia in mice with targeted disruption of the
p27kip1 gene [42-47]. Some of the most dramatic phenotypic
changes in these animals were involved in the retina. For
example, Nakayama et al. reported that the RPE exhibited an
increase in thickness in its apical to basal dimension compared
to  that  seen  in  the  congenic  C57BL/6J  strain  [44].  Other
results showed that the neural retina exhibited focal areas of
Figure 7. Proposed mechanisms of PKCα regulation on PVR. PKCα
affects  cell  proliferation  and  PVR  in  human  RPE  cells  through
negative feedback of p27kip1.
dysplasia,  attributed  to  extended  histogenesis  of
photoreceptors and Müller cells and to the displacement of
reactive glia into the layer of photoreceptor outer segments,
leading to a disruption in the normal organization of the outer
nuclear layer [45,46]. Defoe et al. examined the retinas of
p27kip1 knockout mice in more detail and not only found that
p27kip1 was an important factor in regulating RPE proliferation
during development, but also observed that this protein may
be  a  crucial  factor  involved  in  generating  appropriately
polarized  epithelial  cells  and  in  the  construction  of  the
photoreceptor-RPE interface [47]. From these results, it was
concluded that p27kip1 downregulation may be involved in the
process of RPE cell proliferation and PVR disease. In our
study, p27kip1 was downregulated by PKCα activation at the
gene and protein levels in RPE cells. Moreover, p27kip1 and
PKCα colocalized within the cells, as shown in Figure 6.
Therefore, inhibitors of PKCα could have antiproliferative
effects on RPE cells in vitro and as a potential therapeutic drug
for PVR via p27kip1 downregulation. In addition, a possible
role of PKCδ in cell cycle progression and proliferation in RPE
cells should be ruled out in the future study.
On the other hand, several studies have reported the PKC-
induced  upregulation  of  p27  in  other  cell  types  [48-50];
however, this was associated with cell cycle blocks, unlike the
case  for  RPE  cells  reported  here.  Taken  together,  the
relationship between PKCα, p27kip1, and PVR is illustrated in
Figure 7.
It is well known that PVR is a result of various biologic
reactions, such as the synthesis of the extracellular matrix,
contraction  of  membranes,  and  apoptotic  change  of
photoreceptors. Of all the cells involved in PVR, the RPE cell
is a central player, but the inhibition of RPE cell proliferation
is not sufficient to inhibit PVR, which has been proven by
studies of anticancer drugs for PVR since the 1990s.
In summary, we have found that PKCα affects the cell
cycle progression and proliferation in RPE cells through the
downregulation of p27kip1. These results suggest that PKCα can
be used as a potential therapeutic target against RPE cell
proliferation and PVR disease.
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